Practical Guide to Hereditary Breast and Ovarian Cancer III

This book is a curated collection of research and perspectives of hereditary breast and ovarian cancers (HBOC). With contributions from leading experts in the field, the book provides a valuable resource for a holistic view of the genetic basis, clinical developments and societal implications of these critical diseases. Hence it bridges the gap between science and real-world applications and aims to contribute to empower clinicians’ treatment decisions in HBOC care.

The practice for HBOC has been rapidly increasing due to the clinical development of poly(ADP-ribose) polymerase inhibitors and the spread of companion diagnostics, and it has been changing drastically with the insurance coverage of a part of HBOC treatment in Japan. This volume is based on the best-chosen works presented at JOHBOC and a special chapter delivers a study based on the Society’s extensive database of Japanese HBOC patients, presenting novel evidence for further advancement in the field.

Practical Guide to Hereditary Breast and Ovarian Cancer III - Annual Meeting of the JOHBOC is realized in the background of the remarkable changes in social conditions surrounding HBOC practice and the editors and the authors aim to contribute to the equalization and the widespread of HBOC practice in Japan by sharing the latest information on HBOC practice with medical practitioners, making it useful for their future treatment through this book.

Tomohiko Ohta is a professor at St. Marianna University Graduate School of Medicine. He was the first to show that RING finger motif was responsible for ubiquitin E3 ligase activity, and subsequently found that one of such protein, BRCA1, was an E3 ligase. He graduated St. Marianna University School of Medicine in 1985, received his PhD from the university in 1991, and had acted as a surgeon in the university hospital until 2010. He was professor at graduate school of the university since 2010, where his interest has been focusing on basic breast cancer research including BRCA1. His awards include the award from Japanese Breast Cancer Society, Tokyo Biochemical Research Foundation and Kobayashi Foundation for Cancer Research.

Hiroji Iwata is Vice Director and Chief of Breast Oncology at Aichi Cancer Center Hospital, He is also a Clinical Professor at Nagoya City University Medical School. He is an author of over 200 publications on a wide range of subjects inthe treatment of early stage and metastatic breast cancer. He is a director of Breast Cancer Study Group in Japan Clinical Oncology Group (JCOG), a steering committee member in many global clinical trials. He was a president of Japan Breast Cancer Society annual meeting (2020) and is a president of 21th Japanese Society of Medical Oncology (JSMO) annual meeting in 2024.

Nao Suzuki is a Professor and Chair of the Department of Obstetrics and Gynecology at St. Marianna University School of Medicine, Kanagawa, Japan since 2011. He established the Japan Society for Fertility Preservation in 2012 and the Asian Society for Fertility Preservation in 16 countries in Asia in 2016. He is the President of the International Society for Fertility Preservation from 2023/1 till 2024/12. The gynecologic oncologist, who is the patient's primary caregiver, should perform fertility-sparing surgery with a complete understanding not only of ART and FP but also of preconception care and social issues. Therefore, as a board member of the Asian Society of Gynecologic Oncology, he organized the Special Task Force, Fertility Preservation in Gynecologic Oncology and share country-specific differences and cultural competencies. His wish is to improve CAYA cancer survivorship not only in Asia but also in the world so that patients can fight cancer with hope.